2020 American Transplant Congress
Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kideney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous trials in kidney transplantation (KT) have described a 12-week course of direct-acting anti-viral drugs (DAA) to treat HCV transmission from infected donors to…2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…2020 American Transplant Congress
The Safety and Effectiveness and of Isoniazid Empirical Prophylaxis Compared to Screening Based Prophylaxis Post Lung Transplantation
*Purpose: Even though guidelines recommend using isoniazid (INH) for TB prophylaxis depending on donors and recipients’ screening tests, previous studies supported its use in all…2020 American Transplant Congress
Alternate Triazole Therapy for Breakthrough Invasive Fungal Disease in Lung Transplant Recipients on Triazole Prophylaxis
Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Invasive fungal diseases (IFD) are a leading cause of infection related morbidity and mortality in lung transplant (LT) recipients. Data regarding outcomes of breakthrough…2020 American Transplant Congress
Isavuconazole (ISA) versus Voriconazole (VOR) Prophylaxis (px) in Lung Transplant Recipients (LTR)
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: IFI is a significant complication following lung transplant (LT). VOR was universal antifungal (AF) px in our LT program from 2004-09/2015, at which time…2020 American Transplant Congress
Antimicrobial Prophylaxis Post Antibody Mediated Rejection Treatment in Pediatric Kidney Transplant Recipients: Interim Report from the Paramour “PediAtric Renal AMr Outcomes” Study
*Purpose: Universal guidelines do not exist for post antibody mediated rejection (AMR) treatment antimicrobial prophylaxis (ppx) in pediatric kidney transplant (KT) recipients. We sought to…2020 American Transplant Congress
Stewardship Effortsto Eliminate Post-Orthotopic Liver Transplant Antibiotics in Uncomplicated Patients Leads to Equivalent Safety Outcomes
University of Virginia Health System, Charlottesville, VA
*Purpose: The purpose of this study was to evaluate safety and efficacy endpoints of a revised post-operative antibiotic prophylaxis protocol in orthotopic liver transplant (OLT)…2020 American Transplant Congress
Pneumocystis Pneumonia Occurrence and Prophylaxis Duration in Kidney Transplant Recipients According to Perioperative Treatment with Rituximab
Department of Surgery, Division of Kidney and Pancreas Transplant, AMC, Seoul, Korea, Republic of
*Purpose: Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving…2020 American Transplant Congress
Role of Tacrolimus Dose Adjustment at Discontinuation of Fluconazole in Liver Transplant
University of Virginia Health System, Charlottesville, VA
*Purpose: The purpose of this study was to characterize the effects of fluconazole (fluc) discontinuation on tacrolimus (tac) levels and the role of prophylactic dose…2020 American Transplant Congress
Letermovir for CMV Prophylaxis and Treatment of Resistant/ Refractory CMV Disease in Solid Organ Transplant Recipients
*Purpose: Letermovir (LMV) is approved for primary cytomegalovirus (CMV) prophylaxis in hematopoietic cell transplant recipients. Current FDA-approved antiviral options are limited to foscarnet and cidofovir…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »